Please ensure Javascript is enabled for purposes of website accessibility

Eli Lilly Leaps Past Regeneron's COVID-19 Treatment Candidate

By Cory Renauer – Jun 3, 2020 at 5:13AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

In the race to develop an effective new coronavirus treatment, one of the West Coast's premier biotechnology companies just got lapped by the oldest pharmaceutical giant in the Midwest.

New coronavirus treatments are racing along the development timeline so quickly that it's hard to tell who's in the lead from one moment to the next. Until recently, Regeneron Pharmaceuticals (REGN 1.32%) appeared to be furthest ahead with a new COVID-19 treatment, but Eli Lilly (LLY 0.19%) and the big pharmaceutical company's new collaboration partner, AbCellera, have already beaten Regeneron to an important milestone.

Eli Lilly recently began dosing patients with LY-CoV555, an experimental antibody that was isolated from one of the first U.S. patients to recover from COVID-19. Regeneron's been progressing at top speed with a similar program called REGN-COV2, but patients aren't expected to begin taking it until later this month.

Businessperson leaping over a hurdle

Image source: Getty Images.

What's in store for the future of COVID-19 treatment? Here's what you need to know.

Room for improvement

While remdesivir has already received emergency use authorization (EUA) to treat COVID-19 patients, it's a broad-spectrum antiviral that's been around a long time.Gilead Sciences (GILD -1.43%) had already been aiming the candidate at different viruses for a decade, unsuccessfully, when SARS-CoV-2 reared its ugly head.

Despite remdesivir's early entry, its limited benefit means demand for a highly effective COVID-19 treatment will probably still be sky-high once we know more about LY-CoV555. While there's some evidence remdesivir boosts recovery rates, there's still a lot of room for improvement. Gilead recently released results from the phase 3 Simple trial that show patients' chances of clinical improvement at day 11 were 65% higher when treated with remdesivir plus standard care, compared to patients given standard care and a placebo.

Unfortunately, patients treated with a 10-day course of remdesivir weren't any more likely to show improvement at the same observation point. Deaths were four times more common among patients treated with standard care, but with just six deaths among 583 moderately affected COVID-19 patients in total, the benefit wasn't clear enough to be considered significant.

Remdesivir's a small-molecule drug that inhibits an enzyme hijacked by viruses to replicate themselves. But the LY-CoV555 program is taking a much different approach. Lilly's COVID-19 treatment candidate is a protein that attaches itself to spikes on the surface of SARS-CoV-2, which should prevent the virus from entering host cells in the first place.

A surprising first

Over the past three decades, Regeneron built a reputation for quickly developing new therapeutic antibodies, including an Ebola disease candidate widely expected to be approved by the Food and Drug Administration this fall. Regeneron has employed a similar technique to develop REGN-COV2, a program that will employ a combination of different antibodies working in concert to stop SARS-CoV-2 from replicating.

We know Regeneron's approach worked with Ebola patients during a study conducted in 2018, which makes it a little surprising to see a privately held company appear from nowhere to take the lead in this race. In all fairness to Regeneron, AbCellera had a great deal of help before signing a collaboration deal with Eli Lilly: from the Defense Advanced Research Projects Agency (DARPA) -- an agency tasked with developing emerging technology for use by the military -- and the National Institute of Allergy and Infectious Diseases (NIAID).

A $100 bill with Benjamin Franklin wearing a mask

Image source: Getty Images.

Something to gain?

Investors considering shares of Eli Lilly or Gilead Sciences should know that COVID-19 therapies probably aren't going to make a major impact on their bottom lines, at least not for very long. While LY-CoV555 sales could be a big windfall for most drugmakers, Eli Lilly already has nine products on pace to generate more than $1 billion in sales this year. And over the past twelve months, Gilead Sciences reported $22.7 in total revenue.

Annual sales of Tamiflu peaked at $1.8 billion, and it's an orally available therapy. We don't know if LY-CoV555 will be delivered in the form of an injection or an infusion, but it won't be an easy oral treatment. While sales of a COVID-19 treatment might not make a big difference to Eli Lilly, Regeneron's a smaller, younger company. Over the past year, the biotech reported $8.0 billion in total sales.

During the first three months of 2020, Regeneron leaned on its top-selling product, a blindness-preventing injection called Eylea, for 64% of total sales. Unfortunately for Regeneron and its shareholders, incoming competition could begin pressuring sales of Eylea around a year from now.

Cory Renauer owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
$311.46 (0.19%) $0.59
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
$697.33 (1.32%) $9.07
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$62.86 (-1.43%) $0.91

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.